Gilead Sciences: Truly a Value Stock

Piper Jaffray’s Joshua Schimmer and Jerry Yang explain why Gilead Sciences (GILD) is now a value stock (and contrasts the initial reaction to its earnings with the reaction to Biogen Idec’s (BIIB) results yesterday): AP Gilead Sciences’ Hepatitis-C medication Sovaldi Yet again, Gilead easily surpassed top/bottom line numbers but contracted LT growth prospects, so EPS beats are still being [...]